ArticleJournal of cachexia, sarcopenia and muscle2016
Evaluation of C-terminal Agrin Fragment as a marker of muscle wasting in patients after acute stroke during early rehabilitation.
Article in Journal of cachexia, sarcopenia and muscle, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03477721 (The Role of the Muscle-nervous System Interface in Cancer Cachexia), which is not on this map. Cited by 41 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Role of the Muscle-nervous System Interface in Cancer Cachexia
Who cites it
41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 61 citations in OpenAlex.
- C-Terminal Agrin Fragment as a Biomarker for Sarcopenia: A Systematic Review and Meta-Analysis.Journal of cachexia, sarcopenia and muscle · 2025Pooled it
- Role of Agrin in tissue repair and regeneration: From mechanisms to therapeutic opportunities (Review).International journal of molecular medicine · 2024Pooled it
- Serum C-Terminal Agrin Fragment With Acute and Long-Term Exercise and Angiotensin II Type I Receptor Blockade.Journal of cachexia, sarcopenia and muscle · 2025Trial
- Effects of a 2-year exercise training on neuromuscular system health in older individuals with low muscle function.Journal of cachexia, sarcopenia and muscle · 2023Trial
- [Sarcopenia: diagnosis, clinical implications, and treatment].Innere Medizin (Heidelberg, Germany) · 2026Review
- Critical Assessment of Optimal Timing to Initiate Post-Stroke Rehabilitation.Archives of internal medicine research · 2026Article
- Seric Molecular Markers Correlated with Stroke Rehabilitation Outcomes: A Narrative Review.Life (Basel, Switzerland) · 2026Review
- Proteomics of aging: biomarkers for physiological systems and diseases.Frontiers in aging · 2026Review
- Longitudinal Assessment of Blood-Based Inflammatory, Neuromuscular, and Neurovascular Biomarker Profiles in Intensive Care Unit-Acquired Weakness: A Prospective Single-Center Cohort Study.Neurocritical care · 2025Observational
- Article
- Effect of targeted intervention on C-terminal agrin fragment and its association with the components of sarcopenia: a scoping review.Aging clinical and experimental research · 2023Article
- A human skeletal muscle stem/myotube model reveals multiple signaling targets of cancer secretome in skeletal muscle.iScience · 2023Article
- C-terminal agrin fragment as a biomarker of muscle wasting and weakness: a narrative review.Journal of cachexia, sarcopenia and muscle · 2023Review
- Critical Illness Myopathy Alters Diaphragm Neuromuscular Junction Protein and Gene Expression.American journal of respiratory and critical care medicine · 2023Article
- Review
- Role of noncoding RNAs in pancreatic ductal adenocarcinoma associated cachexia.American journal of physiology. Cell physiology · 2022Review
- Predictive nomogram for soft robotic hand rehabilitation of patients with intracerebral hemorrhage.BMC neurology · 2022Article
- Evaluation of Sarcopenia Using Biomarkers of the Neuromuscular Junction in Parkinson's Disease.Journal of molecular neuroscience : MN · 2022Article
- The relevance of nutritional and metabolic derangements in COVID-19 patients.European journal of internal medicine · 2022Article
- Determination of Agrin and Related Proteins Levels as a Function of Age in Human Hearts.Frontiers in cardiovascular medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundC-terminal Agrin Fragment (CAF) has been proposed as a novel biomarker for sarcopenia originating from the degeneration of the neuromuscular junctions. In patients with stroke muscle wasting is a common observation that predicts functional outcome. We aimed to evaluate agrin sub-fragment CAF22 as a marker of decreased muscle mass and physical performance in the early phase after acute stroke.
methodsPatients with acute ischaemic or haemorrhagic stroke (n = 123, mean age 70 ± 11 y, body mass index BMI 27.0 ± 4.9 kg/m(2)) admitted to inpatient rehabilitation were studied in comparison to 26 healthy controls of similar age and BMI. Functional assessments were performed at begin (23 ± 17 days post stroke) and at the end of the structured rehabilitation programme (49 ± 18 days post stroke) that included physical assessment, maximum hand grip strength, Rivermead motor assessment, and Barthel index. Body composition was assessed by bioelectrical impedance analysis (BIA). Serum levels of CAF22 were measured by ELISA.
resultsCAF22 levels were elevated in stroke patients at admission (134.3 ± 52.3 pM) and showed incomplete recovery until discharge (118.2 ± 42.7 pM) compared to healthy controls (95.7 ± 31.8 pM, p < 0.001). Simple regression analyses revealed an association between CAF22 levels and parameters of physical performance, hand grip strength, and phase angle, a BIA derived measure of the muscle cellular integrity. Improvement of the handgrip strength of the paretic arm during rehabilitation was independently related to the recovery of CAF22 serum levels only in those patients who showed increased lean mass during the rehabilitation.
conclusionsCAF22 serum profiles showed a dynamic elevation and recovery in the subacute phase after acute stroke. Further studies are needed to explore the potential of CAF22 as a serum marker to monitor the muscle status in patients after stroke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.